# Constronics Inf (NSE: CONSTRONIC) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/CONSTRONIC · Pivot · prices to 22 Oct 2026

With a market capitalisation of ₹57 Cr, it ranks 3001st by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Engineering & Construction.

Its return on equity was 8.1% in FY25. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹7 Cr (−61.2% year on year) and net profit ₹0 Cr (−83.3%), on a consolidated basis. Promoters held 10.63% of the company as of 30 Jun 2026; 99.99% of promoter shares were pledged.

## Key numbers

| Metric | Value |
| --- | --- |
| Market cap | ₹57 Cr |
| ROE | 8.1% (FY25) |
| ROCE | 11.5% (FY25) |
| Debt to equity | 0 |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY26 | ₹7 Cr | −61.2% | ₹0 Cr | −83.3% | ₹0.14 |
| Q3 FY26 | ₹9 Cr | −43.0% | ₹0 Cr | −67.7% | ₹0.25 |
| Q2 FY26 | ₹20 Cr | +42.5% | ₹1 Cr | +9.0% | ₹1.07 |
| Q1 FY26 | ₹13 Cr | +345.5% | ₹1 Cr | — | ₹0.80 |
| Q4 FY25 | ₹18 Cr | — | ₹1 Cr | — | ₹0.81 |
| Q3 FY25 | ₹16 Cr | — | ₹1 Cr | — | ₹0.76 |
| Q2 FY25 | ₹14 Cr | — | ₹1 Cr | — | ₹0.98 |
| Q1 FY25 | ₹3 Cr | — | −₹0 Cr | — | −₹0.05 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹51 Cr | ₹3 Cr |
| FY24 | ₹1 Cr | ₹1 Cr |
| FY23 | ₹1 Cr | ₹0 Cr |
| FY22 | ₹2 Cr | ₹0 Cr |
| FY21 | ₹2 Cr | −₹0 Cr |
| FY20 | ₹2 Cr | ₹0 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 10.63%
- Non-institutions: 89.37%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Samrat Pharma](https://app.pivotnow.in/stock/SAMRATPH) | — | ₹61 Cr | — | — |
| [Royal Sense](https://app.pivotnow.in/stock/ROYAL) | — | ₹59 Cr | — | — |
| [Bacil Pharma](https://app.pivotnow.in/stock/BACPHAR) | — | ₹58 Cr | — | — |
| [Veerhealth Care](https://app.pivotnow.in/stock/VEERHEALTH) | — | ₹58 Cr | — | — |
| [Kabra Drugs](https://app.pivotnow.in/stock/KABRADG) | — | ₹56 Cr | — | — |
| [Bandaram Pharma](https://app.pivotnow.in/stock/BANDARAM) | — | ₹53 Cr | — | — |

## Questions and answers

### What is the market cap of Constronics Inf?

Constronics Inf's market capitalisation is ₹57 Cr (₹57 Cr) at the 22 Oct 2026 close, ranking 3001st among the NSE companies Pivot tracks.

### What is the ROE and ROCE of Constronics Inf?

Return on equity was 8.1% in FY25 and return on capital employed was 11.5% in FY25 (standalone figures).

### Is Constronics Inf a debt-free company?

Constronics Inf is close to debt-free: its debt-to-equity ratio was 0 in FY25.

### What were Constronics Inf's latest quarterly results?

For Q4 FY26 (quarter ended 31 Mar 2026), Constronics Inf reported revenue of ₹7 Cr, −61.2% year on year, and net profit of ₹0 Cr, −83.3% year on year.

### What is the shareholding pattern of Constronics Inf?

As of 30 Jun 2026: promoters 10.63%, non-institutions 89.37%. 99.99% of promoter shares were pledged.

### Who are Constronics Inf's competitors?

The listed Pharma & Healthcare companies closest to Constronics Inf by market cap are Samrat Pharma, Royal Sense, Bacil Pharma, Veerhealth Care, Kabra Drugs and Bandaram Pharma.

### Is Constronics Inf a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Constronics Inf's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on CONSTRONIC against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.